Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$32.86

-0.19 (-0.57%)

, AGN

Allergan

$230.31

-0.49 (-0.21%)

06:58
10/03/16
10/03
06:58
10/03/16
06:58

AstraZeneca out-licenses potential inflammatory diseases medicine to Allergan

AstraZeneca (AZN) announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan (AGN) for the global rights to MEDI2070. MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn's disease and is ready for Phase II for ulcerative colitis. These diseases are outside AstraZeneca's three main therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. MedImmune will continue the ongoing Phase II trials until a mutually-agreed transition date. Under the terms of the agreement, Allergan will make an upfront payment to AstraZeneca of $250M for the exclusive, worldwide licence to develop and commercialise MEDI2070. In addition, Allergan may make potential additional payments to AstraZeneca of up to $1.27B, dependent on the achievement of agreed upon success-based development and sales-related milestones, and pay tiered royalties on potential sales of the medicine. MedImmune has been leading the clinical development for MEDI2070 under a collaboration agreement AstraZeneca entered into with Amgen (AMGN) in March 2012. Under the conditions of this agreement, AstraZeneca will subsequently pay Amgen one third of all payments and royalties received from Allergan. Amgen will also receive a single-digit percentage inventor royalty on MEDI2070.

AZN

AstraZeneca

$32.86

-0.19 (-0.57%)

AGN

Allergan

$230.31

-0.49 (-0.21%)

AMGN

Amgen

$166.81

1.36 (0.82%)

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 16

    Nov

  • 19

    Jul

AZN AstraZeneca
$32.86

-0.19 (-0.57%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AGN Allergan
$230.31

-0.49 (-0.21%)

09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
AMGN Amgen
$166.81

1.36 (0.82%)

09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

MRVL

Marvell

$18.03

-0.12 (-0.66%)

11:50
09/21/17
09/21
11:50
09/21/17
11:50
Options
Put buyers active in Marvell as shares tick higher »

Put buyers active in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

TSLA

Tesla

$373.91

-1.19 (-0.32%)

11:48
09/21/17
09/21
11:48
09/21/17
11:48
Periodicals
Tesla to stop selling cheapest Model S this weekend, Business Insider says »

Tesla will stop offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

FANG

Diamondback Energy

$97.32

3.04 (3.22%)

11:45
09/21/17
09/21
11:45
09/21/17
11:45
Hot Stocks
Diamondback Energy EVP Molnar sells 5,000 shares »

Diamondback Energy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FINL

Finish Line

$9.43

-0.13 (-1.36%)

11:40
09/21/17
09/21
11:40
09/21/17
11:40
Options
Large spread in Finish Line ahead of earnings »

Large spread in Finish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:40
09/21/17
09/21
11:40
09/21/17
11:40
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

SQ

Square

$28.24

-0.23 (-0.81%)

, INTC

Intel

$37.07

-0.16 (-0.43%)

11:32
09/21/17
09/21
11:32
09/21/17
11:32
Hot Stocks
Square names Intel's Naveen Rao to board »

Square (SQ) announced…

SQ

Square

$28.24

-0.23 (-0.81%)

INTC

Intel

$37.07

-0.16 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 05

    Oct

  • 22

    Oct

WASH

Washington Trust

$53.05

0.15 (0.28%)

11:31
09/21/17
09/21
11:31
09/21/17
11:31
Hot Stocks
Washington Trust increases quarterly dividend by 1c »

The board of Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$21.15

-0.14 (-0.66%)

, CRZBY

Commerzbank

$13.02

0.28 (2.20%)

11:30
09/21/17
09/21
11:30
09/21/17
11:30
Periodicals
UniCredit expresses interest in Commerzbank merger, Reuters reports »

UniCredit recently…

UNCFF

UniCredit

$21.15

-0.14 (-0.66%)

CRZBY

Commerzbank

$13.02

0.28 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIH

Oil Services Holders Trust

$24.86

-0.33 (-1.31%)

11:30
09/21/17
09/21
11:30
09/21/17
11:30
Options
Short-term call buyers drilling for profits in Market Vectors Oil Services Fund »

Short-term call buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$98.12

1.92 (2.00%)

11:29
09/21/17
09/21
11:29
09/21/17
11:29
Hot Stocks
Intercept sinks after FDA safety communication cites 19 patient deaths »

The FDA, in its safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOR

ShoreTel

11:25
09/21/17
09/21
11:25
09/21/17
11:25
Hot Stocks
Breaking Hot Stocks news story on ShoreTel »

Gardner Lewis reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.46

1.46 (1.52%)

11:25
09/21/17
09/21
11:25
09/21/17
11:25
Periodicals
Equifax CEO to testify to Senate panel on October 4, Bloomberg says »

The Senate Banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FSLR

First Solar

$48.85

-0.01 (-0.02%)

, SPWR

SunPower

$7.86

-0.51 (-6.09%)

11:24
09/21/17
09/21
11:24
09/21/17
11:24
Hot Stocks
Before the Move: Watch First Solar, others ahead of ITC decision »

With an ITC Section 201…

FSLR

First Solar

$48.85

-0.01 (-0.02%)

SPWR

SunPower

$7.86

-0.51 (-6.09%)

CSIQ

Canadian Solar

$16.02

-0.69 (-4.13%)

JKS

JinkoSolar

$26.13

-0.16 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLNG

Golar LNG

$21.15

0.66 (3.22%)

11:20
09/21/17
09/21
11:20
09/21/17
11:20
Options
Golar LNG calls active as shares see relative strength »

Golar LNG calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
09/21/17
09/21
11:17
09/21/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
09/21/17
09/21
11:16
09/21/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$81.16

-0.64 (-0.78%)

11:15
09/21/17
09/21
11:15
09/21/17
11:15
Options
Capital One put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

11:15
09/21/17
09/21
11:15
09/21/17
11:15
General news
Treasury announced an $88 B 3-pronged package of coupon auctions »

Treasury announced an $88…

PEG

PSEG

$46.31

1.08 (2.39%)

11:10
09/21/17
09/21
11:10
09/21/17
11:10
Conference/Events
PSEG management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 05

    Nov

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
5-Yr Note Announcement Offering Amount data reported »

5-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
2-Yr Note Announcement CUSIP Number data reported »

2-Yr Note Announcement…

11:08
09/21/17
09/21
11:08
09/21/17
11:08
General news
2-Yr Note Announcement Offering Amount data reported »

2-Yr Note Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.